If its promising data hold up when released in full, the ALS drug from Amylyx Pharmaceuticals could lead a wave of new treatments for the progressive, fatal disease
An experimental drug slowed the paralyzing march of amyotrophic lateral sclerosis, or Lou Gehrig’s disease, in a clinical trial, according to researchers who say the results are a fresh sign that recent insights into the condition may soon bring new medicines.
The drug’s maker, closely held Amylyx Pharmaceuticals Inc., is releasing only the barest outlines of the mid-stage trial for now, as researchers continue to analyze the results. The drug slowed the rate of ALS’s progression in patients as measured by a widely used scale,...
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
BeiGene cancer drug fails in study against AbbVie: J&J's ImbruvicaBeiGene Ltd said on Monday a late-stage trial failed to show that its cancer tre...
Lire la suite »
Axsome shares surge 75% after depression drug reduces symptoms in late-stage studyMajor depressive disorder (MDD) is a chronic condition that makes patients feel low, experience guilt and worthlessness and, in some cases, may lead to suicide. There are few treatments available to people suffering from depression and some of these carry significant side effects. A large number of
Lire la suite »
FDA approves fish-oil drug for cutting cardiac risksIn patient testing, the drug reduced risks of potentially deadly complications including heart attacks and strokes about 25 percent.
Lire la suite »
Democrats box in Republicans on drug pricingSenate Republicans aren't sure how to respond to House Democrats finally passing a massive bill aimed at lowering drug prices
Lire la suite »
Novartis Drops Asthma Drug After Disappointing Trial ResultsNovartis said it was abandoning fevipiprant, a potential blockbuster drug in asthma, after it failed two late stage-trials, dealing a blow to the company’s hopes of pioneering a novel way to treat the respiratory disease.
Lire la suite »